Zonisamide treatment for symptomatic infantile spasms.
The authors evaluated zonisamide for symptomatic infantile spasms in 23 patients. Spasm cessation, EEG evolution, and tolerability were assessed for a mean duration of 6.5 months. Six patients (26%) had complete control with cessation of spasms and clearing of hypsarrhythmia. Mean latency time from onset of zonisamide treatment to complete spasm control was 19 days. There were no discontinuations due to adverse effects.
Lotze
Timothy E
TE
Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Wilfong
Angus A
AA
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007223:Infant; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D013036:Spasms, Infantile / Q000188:drug therapy*; D016896:Treatment Outcome; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide